Compare RM & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | BIOA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.1M | 255.6M |
| IPO Year | 2011 | 2024 |
| Metric | RM | BIOA |
|---|---|---|
| Price | $33.29 | $4.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $44.33 | $28.78 |
| AVG Volume (30 Days) | 73.6K | ★ 614.4K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 7.49 | ★ 66.21 |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $645,598,000.00 | $8,995,000.00 |
| Revenue This Year | $12.14 | N/A |
| Revenue Next Year | $6.26 | $114.74 |
| P/E Ratio | $9.39 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $29.89 | $4.81 |
| 52 Week High | $44.30 | $25.96 |
| Indicator | RM | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 31.71 |
| Support Level | $31.05 | N/A |
| Resistance Level | $34.66 | $6.30 |
| Average True Range (ATR) | 1.66 | 0.44 |
| MACD | -0.41 | -0.02 |
| Stochastic Oscillator | 8.68 | 17.07 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.